The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?
Featured:
Abdul-Hamid BazarbachiDuring the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Abdul-Hamid Bazarbachi, Jacobi Medical Centre, New York, US. We asked, Is combination anti-thymocyte globulin (ATG) + post-transplantation cyclophosphamide (PTCy) prophylaxis always preferable to using each agent separately in haploidentical hematopoietic cell transplant (haplo-HCT)?
Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?
Bazarbachi begins by outlining the indications and efficacy of both high-dose PTCy and ATG as sole therapies in GvHD prophylaxis. He goes on to discuss recent clinical research presented at the 49th Annual Meeting of the EBMT on the use of these treatments concurrently, with a focus on engraftment, relapse, and overall survival. Bazarbachi concludes by describing the implications of this data for the management of patients post haplo-HCT and the resulting incidence of GvHD.
